Day: September 7, 2021

BOSTON, Sept. 07, 2021 (GLOBE NEWSWIRE) — Atea Pharmaceuticals, Inc. (Nasdaq: AVIR) (“Atea”), a clinical-stage biopharmaceutical company, today announced that Jean-Pierre Sommadossi, PhD, Chief Executive Officer and Founder of Atea together with other members of the Atea management team, will participate in a fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Tuesday, September 14, 2021 at 2:00 p.m. ET. A live webcast of the presentation will be available here and on the Company’s website at www.ateapharma.com. A replay of the webcast will be available for 90 days following the presentation. About Atea Pharmaceuticals Atea Pharmaceuticals is a clinical stage biopharmaceutical company focused on discovering, developing and commercializing oral therapies to address the unmet medical needs of patients...

ELMS Crash Test 1Images from ELMS’ crash testingELMS Crash Test 2Images from ELMS’ crash testing– Urban Delivery Vehicle Expected to be First Commercial Class 1 Electric Vehicle in the U.S. – Structural Crash Tests and Engineering Validation Phase Complete TROY, Mich., Sept. 07, 2021 (GLOBE NEWSWIRE) — Electric Last Mile Solutions, Inc. (Nasdaq: ELMS or ELMSW) (“ELMS” or “the Company”), a pure-play commercial electric vehicle (“EV”) company focused on redefining productivity for the last mile, today announced that it successfully completed structural confirmation impact testing for its Urban Delivery commercial class 1 vehicle. With this phase complete, the body design has been frozen. Testing took place at the NHTSA validated Calspan facility in Buffalo, NY. James Taylor,...

BOSTON and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) — Orchard Therapeutics (Nasdaq: ORTX), a global gene therapy leader, today announced that the Compensation Committee of Orchard’s Board of Directors approved the grant of non-statutory stock options to four new employees to purchase an aggregate of 278,500 ordinary shares under Orchard’s 2020 Inducement Equity Plan. The awards were granted as an inducement material to the employees’ acceptance of employment with Orchard in accordance with Nasdaq Listing Rule 5635(c)(4). The options have an exercise price of $3.09 per share, which is equal to the closing price of Orchard’s American Depositary Shares as reported by Nasdaq on September 1, 2021. The options have a ten-year term and vest over four years, with 25% vesting on the one-year anniversary of the employee’s date of hire and...

Table 1Significant Diamond Drilling Results, Iska Iska, as at September 5, 2021Figure 1Geology of the Iska Iska Caldera Complex showing locations of Major Breccia Pipe targets including the magnetic anomaly northwest of the Santa Barbara Breccia Pipe and diamond drill holes completed and in progress.Figure 2North-South Geological Cross Section, Santa Barbara Breccia Pipe showing Major Extension in Holes DSB-12 and DSB-13Figure 3a: Picture of Diamond Drill Core Samples from Hole DSB-12Hole DSB-12 496.27m to 503.44m. Deformed moderately alunitized dacite locally interbedded with minor sandstone, showing flow banding and cut by intrusive breccia composed of dacite clasts cemented with tourmaline matrix (partially replaced by sulphides as pyrite, sphalerite and, silver sulphosalts)....

BELTSVILLE, Md., Sept. 07, 2021 (GLOBE NEWSWIRE) — NextCure, Inc. (Nasdaq: NXTC), a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases, today announced that it will present at the H.C. Wainwright 23rd Annual Global Investment Conference on September 13th. An audio webcast of the pre-recorded presentation will be available on the Investors section of the company’s website at www.nextcure.com. A replay of the webcast will be available after the event and archived on the website for 30 days. About NextCure, Inc.NextCure is a clinical-stage biopharmaceutical company committed to discovering and developing novel, first-in-class immunomedicines to treat cancer and other immune-related diseases. Through our proprietary...

LATHAM, N.Y., Sept. 07, 2021 (GLOBE NEWSWIRE) — Latham Group, Inc. (NASDAQ: SWIM) (“Latham” or “the Company”), the largest designer, manufacturer and marketer of in-ground residential swimming pools in North America, Australia and New Zealand, today announced its participation in the following investor conferences: Goldman Sachs 28th Annual Global Retailing Conference Date: September 10, 2021Fireside Chat: 3:20 PM EDTParticipants: Scott Rajeski, President and Chief Executive Officer, Mark Borseth, Chief Financial Officer Morgan Stanley 9th Annual Laguna Conference Date: September 15, 2021Fireside Chat: 8:15 AM EDTParticipants: Scott Rajeski, President and Chief Executive Officer, Mark Borseth, Chief Financial Officer Links to the live webcasts of the fireside chats can be found on the investor relations section of Latham’s website...

MALVERN, Pa., Sept. 07, 2021 (GLOBE NEWSWIRE) — Galera Therapeutics, Inc. (Nasdaq: GRTX), a clinical-stage biopharmaceutical company focused on developing and commercializing a pipeline of novel, proprietary therapeutics that have the potential to transform radiotherapy in cancer, today announced that Mel Sorensen, M.D., President and Chief Executive Officer, will present at three upcoming virtual investor conferences in September. Presentation Details: Event: H.C. Wainwright 23rd Annual Global Investment ConferenceDate: Monday, September 13, 2021 Time: On-demand beginning at 7:00 a.m. ET Event: Oppenheimer Fall Healthcare Life Sciences & MedTech SummitDate: Tuesday, September 21, 2021 Time: 11:35 a.m. ET Event: Cantor Fitzgerald Global Healthcare ConferenceDate: Wednesday, September 29, 2021 Time: 10:00 a.m. ET Live webcasts...

MOUNTAIN VIEW, Calif., Sept. 07, 2021 (GLOBE NEWSWIRE) — IGM Biosciences, Inc. (Nasdaq: IGMS), a clinical-stage biotechnology company focused on creating and developing engineered IgM antibodies, today announced that management will participate in three upcoming investor conferences:Citi 16th Annual BioPharma Virtual Conference on Thursday, September 9 Fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on Monday, September 13 at 2:45 p.m. EDT Fireside chat at Baird’s 2021 Global Consumer, Technology & Services Conference on Tuesday, September 14 at 2:35 p.m. EDTA live webcast of the Morgan Stanley fireside chat will be available on the “Events and Presentations” page in the “Investors” section of the Company’s website at https://investor.igmbio.com/news-and-events/events-and-presentations. A replay...

SOMERVILLE, Mass., Sept. 07, 2021 (GLOBE NEWSWIRE) — Finch Therapeutics Group, Inc. (“Finch” or “Finch Therapeutics”) (Nasdaq: FNCH), a clinical-stage microbiome therapeutics company leveraging its Human-First Discovery® platform to develop a novel class of orally administered biological drugs, today announced that Mark Smith, PhD, Chief Executive Officer, will present a company overview at the H.C. Wainwright 23rd Annual Global Investment Conference being held September 13-15, 2021. The on-demand presentation will be available on Monday, September 13, 2021 at 7:00 am ET. A webcast of the presentation will be available under the ‘Investors & News’ section of the Finch website and will be archived for approximately 30 days. About Finch Therapeutics Finch Therapeutics is a clinical-stage microbiome therapeutics company leveraging...

NEW YORK and LONDON, Sept. 07, 2021 (GLOBE NEWSWIRE) — Akari Therapeutics, Plc (Nasdaq: AKTX), a late-stage biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where complement (C5) and/or leukotriene (LTB4) systems are implicated, today announced that Clive Richardson, Chief Executive Officer, will present at the H.C. Wainwright 23rd Annual Global Investment Conference being held virtually September 13-15, 2021. Investors interested in arranging a virtual meeting with the Company’s management during the conference should contact the H.C. Wainwright conference coordinator. A webcast of the Company’s presentation will be available on-demand beginning September 13, 2021 at 7:00 a.m. ET by visiting ‘Events’ in the Investor Relations section on the Company’s website at www.akaritx.com....